Immunological heterogeneity of multiple sclerosis in Sardinia and Sweden

Multiple Sclerosis

Volumn 11, Issue 1, 2005, Pages 16-23

  Huang, Yu Min ^a   Liu, Xuan ^a   Steffensen, Knut ^a   Sanna, Alessandra ^b   Arru, Giannina ^b   Fois, Maria Laura ^b   Rosati, Giulio ^b   Sotgiu, Stefano ^b   Link, Hans ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

IDO; IL 12; IL 6; Multiple sclerosis; RT PCR; TNF

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 12P40; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; STAT4 PROTEIN; STAT6 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE GENE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; INCIDENCE; INFLAMMATORY DISEASE; ITALY; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; REAL TIME POLYMERASE CHAIN REACTION; SWEDEN; TH1 CELL; TH2 CELL;

ADULT; CYTOKINES; DNA-BINDING PROTEINS; FEMALE; GENETIC HETEROGENEITY; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-18; INTERLEUKIN-18 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; INTERLEUKIN-6; ITALY; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, CYTOKINE; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-10; RECEPTORS, INTERLEUKIN-12; RECEPTORS, INTERLEUKIN-18; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; STAT4 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR; SWEDEN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN OXYGENASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 13844312667     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1127oa     Document Type: Article

References (34)

1. Sundstrom P, Nystrom L, Forsgren L. Incidence (1988-97) and prevalence (1997) of multiple sclerosis in Vasterbotten County in northern Sweden. J Neurol Neurosurg Psych 2003; 74: 29-32.
2. Kurtzke JF. The epidemiology of multiple sclerosis. In Raine CS, McFarland HF, Tourtellotte WW eds. Multiple sclerosis, clinical and pathogenetic basis. London: Chapman and Hall Medical, 1997: 91-139.
3. Underhill PA, Shen P, Lin AA, Jin L, Passarino G, Yang WH et al. Y chromosome sequence variation and the history of human population. Nat Genet 2000; 26: 358-61.
4. Pugliatti M, Sotgiu S, Solinas G, Castiglia P, Pirastra MI, Margia B et al. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta Neurol Scand 2001; 103 20-26.
5. Hoffman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989; 170: 607-12.
6. Balashov KE, Comabella M, Ohashi T, Khoury SJ, Weiner HL. Defective regulation of IFN-gamma and IL-12 by endogenous IL-10 in progressive MS. Neurology 2000; 55: 192-98.
7. Cannella B, Raine CS. Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. Ann Neurol 2004; 55: 46-57.
8. Maimone D, Guazzi GC, Annunziata P. IL-6 detection in multiple sclerosis brain. J Neurol Sci 1997; 146: 59-65.
9. van Boxel-Dezaire AH, Hoff SC, van Oosten BW, Verweij CL, Drager AM, Ader HJ et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999; 45: 695-703.
10. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 2003; 14: 361-68.
11. Watford WT, O'Shea JJ. Autoimmunity: A case of mistaken identity. Nature 2003; 421: 706-708.
12. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N et al. STAT proteins: From normal control of cellular events to tumorigenesis. J Cell Physiol 2003; 197: 157-58.
13. Skundric DS, Lisak RP. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp Diab Res 2003; 4: 303-12.
14. Liebau C, Baltzer AW, Schmidt S, Roesel C, Karreman C, Prisack JB et al. Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteo-sarcoma cell lines independently from interferon-gamma. Anticancer Res 2002; 22: 931-36.
15. Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D. Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003; 10: 1581-91.
16. Grohmann U, Fallarino F and Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 2003; 24: 242-48.
17. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers, GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
18. Ramos-Payan R, Aguilar-Medina M, Estrada-Parra S, Gonzalez YMJ, Favila-Castillo L, Monroy-Ostria A et al. Quantification of cytokine gene expression using an economical real-time polymerase chain reaction method based on SYBR Green I. Scand J Immunol 2003; 57 439-45.
19. Pedotti R, De Voss JJ, Steinman L, Galli SJ. Involvement of both 'allergic' and 'autoimmune' mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol 2003; 24: 479-84.
20. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004; 3: 104-10.
21. Martin R, Sturzebecher CS, McFarland HF. Immunotherapy of multiple sclerosis: Where are we? Where should we go? Nat Immunol 2001; 2: 785-88.
22. Cavalli-Sforza LL, Piazza A. Human genomic diversity in Europe: a summary of recent research and prospects for the future. Eur J Hum Genet 1993; 1: 3-18.
23. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML et al. Expression of costimulatory molecules B7-1 (CD80 , B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995; 182: 1985-96.
24. Fassbender K, Ragoschke A, Rossol S, Schwartz A, Mielke O, Paulig A et al. Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology 1998; 51 753-58.
25. Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR. Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis. J Neuroimmunol 2004; 146: 209-15.
26. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-48.
27. Hollfield RD, Harbige LS, Pham-Dinh D, Sharief MK. Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 2003; 36 133-41.
28. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57: 1885-88.
29. Sotgiu S, Serra C, Marrosu MG, Dolei A, Rosati G. Cytokine production in patients carrying multiple sclerosis-linked HLA-DR alleles. J Neurol 1999; 246: 1194-96.
30. Frei K, Fredrikson S, Fontana A, Link H. Interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol 1991; 31: 147-53.
31. Merberg DM, Wolf SF, Clark SC. Sequence similarity between NKSF and the IL-6/G-CSF family. Immunol Today 1992; 13: 77-78.
32. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19: 225-34.
33. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A et al. Induced indoleamine 2,3-dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171: 1652-55.
34. Xiao BG, Wu XC, Yang JS, Xu LY, Liu X, Huang YM et al. Therapeutic potential of IFN-gamma-modified dendritic cells in acute and chronic experimental allergic encephalomyelitis. Int Immunol 2004; 16: 13-22.